Mirvetuximab Soravtansine Plus Bevacizumab Looks Promising in Platinum-Agnostic Ovarian Cancer

June 7, 2021 11:22 am

The following article is provided by The Clearity Foundation to support women with ovarian cancer and their families. Learn more about The Clearity Foundation and the services we provide directly to women as they make treatment decisions and navigate emotional impacts of their diagnosis.

ASCO logo

The combination of mirvetuximab soravtansine and bevacizumab produces “impressive antitumor activity” in patients with recurrent ovarian cancer and high folate receptor alpha (FRα) expression, according to researchers.

David M. O’Malley, MD, of The Ohio State University Wexner Medical Center in Columbus, and colleagues presented these findings at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.1

The phase 1/2 study (ClinicalTrials.gov Identifier: NCT02606305) included 60 patients with platinum-sensitive (47%) or platinum-resistant (53%) ovarian cancer. The patients received mirvetuximab soravtansine at 6 mg/kg plus bevacizumab at 15 mg/kg on day 1 of a 21-day cycle.

In a recent paper published in the Journal of Clinical Oncology, the authors recommended using adjuvant and maintenance bevacizumab to treat a patient with stage IIIc ovarian cancer following an optimal (R0) resection.
Outcomes were best in patients with high FRα expression and platinum-sensitive disease.

The results presented at ASCO 2021 build on previously published data showing that mirvetuximab soravtansine was well tolerated and produced a confirmed objective response rate (ORR) of 39%.2

At a median follow-up of 17.5 months, the updated results showed an ORR of 47%. The median duration of response (DOR) was 9.7 months, and the median progression-free survival (PFS) was 8.3 months.

Looking specifically at patients with high FRα expression, the ORR increased to 64%, the median DOR was 11.8 months, and the median PFS was 10.6 months.

Among patients with high FRα expression and platinum-resistant disease, the ORR was 59%, the median DOR was 9.4 months, and the median PFS was 10.1 months.

Patients with high FRα expression and platinum-sensitive disease had the highest ORR, at 69%. They also had the longest median DOR, at 12.9 months, and the longest median PFS, at 13.3 months.

Common treatment-related adverse events included diarrhea (68%), blurred vision (63%), fatigue (58%), and nausea (57%). Common grade 3 or worse adverse events included neutropenia and hypertension.

Disclosures: This research was supported by ImmunoGen. Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.

References

  1. O’Malley DM, Oaknin A, Matulonis UA, et al. Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: final analysis. J Clin Oncol. 2021;39:(suppl 15; abstr 5504). doi:10.1200/JCO.2021.39.15_suppl.5504
  2. O’Malley DM, Matulonis UA, Birrer MJ, et al. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancerGynecol Oncol. 2020;157(2):379-385. doi:10.1016/j.ygyno.2020.01.037

This article was published by Cancer Therapy Advisor.

Leave a Reply

Your email address will not be published. Required fields are marked *

Return to Blog Home Return to Clearity Foundation Home